Berger Montague Investigates Securities Class Action Lawsuit Against Rocket Pharmaceuticals

Strategic Insights -

Berger Montague PC, a nationally recognized securities litigation firm, is investigating a newly filed securities class action lawsuit against Rocket Pharmaceuticals, Inc. The suit alleges that the Company misled investors regarding critical safety disclosures tied to its RP-A501 gene therapy program. Rocket Pharmaceuticals, a biotechnology company, focused on developing gene therapies for rare diseases, failed to inform investors of a substantial protocol change prior to a serious adverse event and subsequent FDA clinical hold. Following the Company's disclosure of a patient death in the trial, RCKT shares fell nearly 37% in a short period.

Key Takeaways:

  • Berger Montague is investigating a securities class action lawsuit against Rocket Pharmaceuticals, Inc. alleging the Company misled investors regarding critical safety disclosures tied to its RP-A501 gene therapy program.
  • The lawsuit was filed in the U.S. District Court for the District of New Jersey and alleges that the Company failed to inform investors of a substantial protocol change prior to a serious adverse event (SAE) and subsequent FDA clinical hold.
  • Following the Company's disclosure of a patient death in the trial, RCKT shares fell nearly 37% in a short period.
  • The suit alleges that the Company's failure to provide critical safety disclosures resulted in significant losses for investors.
  • Investors who purchased Rocket Pharmaceuticals securities between September 17, 2024, and May 26, 2025, may be eligible to seek recovery, with a deadline to apply for lead plaintiff of August 11, 2025.
  • Berger Montague has represented individual and institutional investors in securities class action litigation for over five decades.
  • The firm has been a pioneer in securities class action litigation since its founding in 1970 and serves as lead counsel in courts throughout the United States.

Statistics:

  • 37% decline in RCKT shares following the Company's disclosure of a patient death in the trial (from $6.27 on May 23, 2025, to $2.33 on May 27, 2025).
  • $6.27: the closing stock price of RCKT on May 23, 2025.
  • $2.33: the closing stock price of RCKT on May 27, 2025.
  • 52 weeks: the time period in which RCKT shares were traded.
  • May 23, 2025: the date on which RCKT shares closed at $6.27.
  • May 27, 2025: the date on which RCKT shares closed at $2.33.
  • August 11, 2025: the deadline to apply for lead plaintiff in the securities class action lawsuit.

Sources:

  • Newsfile Corp. - July 22, 2025
  • Berger Montague PC
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)